VTYX Ventyx Biosciences, Inc.

Nasdaq ventyxbio.com


$ 3.93 $ -0.08 (-2 %)    

Friday, 17-Oct-2025 15:59:59 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 3.92
$ 3.93
$ 3.78 x 20
$ 4.00 x 6
$ 3.82 - $ 3.98
$ 0.78 - $ 4.12
983,177
na
279.53M
$ 0.90
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 02-27-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 02-27-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-23-2023 12-31-2022 10-K
12 11-04-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-23-2022 12-31-2021 10-K
16 11-18-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 clear-street-initiates-coverage-on-ventyx-biosciences-with-buy-rating-announces-price-target-of-11

Clear Street analyst Kaveri Pohlman initiates coverage on Ventyx Biosciences (NASDAQ:VTYX) with a Buy rating and announces P...

 ventyx-biosciences-q2-eps-038-beats-045-estimate

Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(...

 ventyx-biosciences-q1-eps-039-beats-049-estimate

Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(...

 ventyx-biosciences-q4-eps-041-beats-054-estimate

Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(...

 ventyx-biosciences-announces-presentation-of-data-from-the-phase-2-trial-of-allosteric-tyk2-inhibitor-vtx958-in-crohns-disease-at-ecco-2025

Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markersFull analysi...

 hc-wainwright--co-reiterates-neutral-on-ventyx-biosciencesto-neutral

HC Wainwright & Co. analyst Emily Bodnar reiterates Ventyx Biosciences (NASDAQ:VTYX) from Neutral to Neutral.

 ventyx-announces-phase-2-trials-for-vtx2735-vtx3232-obesity-data-expected-h2-2025-parkinsons-data-h1-2025-2529m-funding-extends-to-h2-2026

First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline ...

 hc-wainwright--co-reiterates-neutral-on-ventyx-biosciences-maintains-6-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Ventyx Biosciences (NASDAQ:VTYX) with a Neutral and maintains $6 pri...

 oppenheimer-reiterates-outperform-on-ventyx-biosciences-lowers-price-target-to-9

Oppenheimer analyst Jeff Jones reiterates Ventyx Biosciences (NASDAQ:VTYX) with a Outperform and lowers the price target fro...

 ventyx-biosciences-q3-eps-050-beats-053-estimate

Ventyx Biosciences (NASDAQ:VTYX) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(...

Core News & Articles

https://blog.tipranks.com/these-2-strong-buy-penny-stocks-could-rally-over-500-say-analysts/

 hc-wainwright--co-reiterates-neutral-on-ventyx-biosciences-maintains-6-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates Ventyx Biosciences (NASDAQ:VTYX) with a Neutral and maintains $6 pri...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION